Our Pipeline

APEIRON is focused on developing therapies to effectively treat respiratory diseases and cancer. Our respiratory platform around ACE2 is specifically targeting COVID-19 as well as ARDS (Acute Respiratory Distress Syndrome) and ALI (Acute Lung Injury). Our immune-oncology pipeline concentrates on next-generation checkpoint inhibitor Cbl-b and novel IO targets to activate the patient’s immune system against various tumors.

Therapeutic area
Technology platform

Projects

Indication

Development phase
Disco­very
Phase 1
Phase 2
Phase 3
Respiratory
rhACE2

APN01 - moderate to severe cases

COVID-19

APN01 - other route of administration

COVID-19

ARDS, ALI

Immuno-Oncology
Cbl-b





Novel IO targets

APN401 - autologous cell therapy

Various solid tumors

APN431 - small molecules

Various tumors

APN411 - small molecules

Partnered with

Various tumors

APN421 - small molecules

Various tumors

Therapeutic area
Technology platform

Projects

Indication

Development phase
Disco­very
Phase 1
Phase 2
Phase 3
Respiratory
rhACE2

APN01 - moderate to severe cases

COVID-19

APN01 - other route of administration

COVID-19

ARDS, ALI

Immuno-Oncology
Novel IO targets Cbl-b

APN401 - autologous cell therapy

Various solid tumors

APN431 - small molecules

Various tumors

APN411 - small molecules

Partnered with

Various tumors

APN421 - small molecules

Various tumors